 WILMETTE, Ill. and BELOIT, Wis., Dec. 10, 2020 GLOBE NEWSWIRE -- Monopar Therapeutics Inc. Nasdaq: MNPR and NorthStar Medical Radioisotopes, LLC, which are jointly developing a urokinase plasminogen activator receptor targeted radio-immuno-therapeutic uPRIT for the potential treatment of severe COVID-19, today announced the selection of a uPRIT clinical candidate. Monopar and NorthStar partnered with IsoTherapeutics Group LLC to generate a panel of uPRIT leads, which were then screened by Aragen Bioscience Inc., resulting in the identification of a uPRIT clinical candidate plus several backup candidates. 